Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 23;8(7):e71118.
doi: 10.1002/hsr2.71118. eCollection 2025 Jul.

Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

Saeed Khorramnia  1 , Zia Navidi  1 , Ali Sarkoohi  1 , Mojgan Mohajeri Iravani  2 , Amirhossein Orandi  3 , Amirali Orandi  4 , Samrand Fattah Ghazi  5 , Ehsan Fallah  6 , Ebadallah Shiri Malekabad  7 , Seyed Hamid Pakzad Moghadam  1
Affiliations
Review

Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

Saeed Khorramnia et al. Health Sci Rep. .

Abstract

Background and aim: Remdesivir and Sotrovimab have emerged as potential treatment options for patients diagnosed with coronavirus disease 2019 (COVID-19). This systematic review and meta-analysis sought to evaluate and compare the effectiveness and safety of these two drugs in the context of COVID-19 management.

Methods: A systematic search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar up to July 2024. The effectiveness outcomes examined included mortality rate, hospitalization rate, emergency department visits, ICU admission, and adverse events. The risk of bias in nonrandomized studies of interventions was evaluated using a standardized tool, and data from the identified studies were meticulously analyzed using Comprehensive Meta-Analysis (CMA) software.

Results: The analysis incorporated a total of 9 studies involving 7841 patients. The meta-analysis findings indicated no significant disparity between the Remdesivir and Sotrovimab groups concerning mortality rate (odds ratio [OR] = 3.49, 95% confidence interval [CI]: 0.50-24.11, p = 0.20), hospitalization rate (OR = 2.11, 95% CI: 0.85-5.22, p = 0.10), emergency department visit (OR = 0.80, 95% CI: 0.11-5.62, p = 0.82), and intensive care unit (2.37, 95% CI: 0.18-29.90, p = 0.50). Moreover, comparable rates of adverse events were observed across both groups (OR = 0.98, 95% CI: 0.39-2.47, p = 0.97). The certainty of evidence for these findings was rated as low or moderate.

Conclusion: The study findings suggest that there is no significant difference in effectiveness between Remdesivir and Sotrovimab in the treatment of COVID-19 patients. Further research is needed to provide a more comprehensive comparison of these interventions for COVID-19.

Keywords: COVID‐19; Remdesivir; SARS‐CoV‐2; Sotrovimab; effectiveness; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of the included studies in the meta‐analysis.
Figure 2
Figure 2
Forest plot illustrating the comparison of mortality rates between Remdesivir and Sotrovimab.
Figure 3
Figure 3
Forest plot illustrating the comparison of hospitalization rates between Remdesivir and Sotrovimab.
Figure 4
Figure 4
Forest plot illustrating the comparison of emergency department visits between Remdesivir and Sotrovimab.
Figure 5
Figure 5
Forest plot illustrating the comparison of ICU admission between Remdesivir and Sotrovimab.
Figure 6
Figure 6
Forest plot illustrating the comparison of adverse events between Remdesivir and Sotrovimab.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Clarke J. A., Wiemken T. L., and Korenblat K. M., “Excess Mortality Among Solid Organ Transplant Recipients in the United States During the COVID‐19 Pandemic,” Transplantation 106, no. 12 (2022): 2399–2407. - PMC - PubMed
    1. Mohamed K., Rzymski P., Islam M. S., et al., “COVID‐19 Vaccinations: The Unknowns, Challenges, and Hopes,” Journal of Medical Virology 94, no. 4 (2022): 1336–1349. - PMC - PubMed
    1. Chen X., Luo D., Mei B., et al., “Immunogenicity of COVID‐19 Vaccines in Solid Organ Transplant Recipients: A Systematic Review and Meta‐Analysis,” Clinical Microbiology and Infection 29, no. 4 (2023): 441–456. - PMC - PubMed
    1. van den Berg J. M., Remmelzwaal S., Blom M. T., et al., “Effectiveness of COVID‐19 Vaccines in Adults With Diabetes Mellitus: A Systematic Review,” Vaccines 11, no. 1 (2022): 24. - PMC - PubMed
    1. Yin J., Chen Y., Li Y., Wang C., and Zhang X., “Immunogenicity and Efficacy of COVID‐19 Vaccines in People Living With HIV: A Systematic Review and Meta‐Analysis,” International Journal of Infectious Diseases 124 (2022): 212–223. - PMC - PubMed

LinkOut - more resources